key: cord-0830471-y61g0hg0 authors: Dogan, M.; Kozhaya, L.; Placek, L.; Gunter, C.; Yigit, M.; Hardy, R.; Plassmeyer, M.; Coatney, P.; Lillard, K.; Bukhari, Z.; Kleinberg, M.; Hayes, C.; Arditi, M.; Klapper, E.; Merin, N.; Liang, B. T.; Gupta, R.; Alpan, O.; Unutmaz, D. title: Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19 date: 2020-07-08 journal: medRxiv : the preprint server for health sciences DOI: 10.1101/2020.07.07.20148106 sha: 0584466a76719a7b27457d4f54896e487efc5449 doc_id: 830471 cord_uid: y61g0hg0 Development of antibody protection during SARS-CoV-2 (CoV-2) infection is a pressing question for public health and for vaccine development. We developed highly sensitive CoV-2-specific antibody and neutralization assays. CoV-2 Spike protein or Nucleocapsid protein specific IgG antibodies at titers more than 1:100,000 were detectable in all PCR+ subjects (n=87) and were absent in the negative controls. Other isotype antibodies (IgA, IgG1-4) were also detected. CoV-2 neutralization was determined in COVID-19 and convalescent plasma up to 10,000-fold dilution, using Spike protein pseudotyped lentiviruses, which was also blocked by neutralizing antibodies (NAbs). Hospitalized patients had up to 3000-fold higher antibody and neutralization titers compared to outpatients or convalescent plasma donors. Further, subjects who donated plasma further out from the diagnosis of COVID-19 appeared to have lower titers. Interestingly, some COVID-19 patients also contained NAbs against SARS Spike protein pseudovirus. Together these results demonstrate the high specificity and sensitivity of our assays, which may impact understanding the quality or duration of the antibody response during COVID-19 and in determining the effectiveness of potential vaccines. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2; CoV-2), which has caused the COVID-19 pandemic, enters the target cells through the interaction of its envelope Spike protein with the primary host cell receptor Angiotensin Converting Enzyme-2 (ACE2), which is then cleaved by a serine protease (TMPRSS2) to allow viral fusion and entry across the cell membrane 1 . Antibodies that can bind to the Spike protein have the potential to neutralize viral geometric mean of expression (Fig. 3b ). As such, we used Spike protein lacking the ERRS for lentiviral pseudotyping to ensure its higher incorporation into viral membranes. We then co-transfected 293 cells with replication defective lentivectors encoding GFP or RFP reporter genes and the Spike protein encoding plasmid and harvested the supernatant at 24 hours, which was then used to infect cells expressing ACE2 (Fig. 3c) . Bald particles were generated by transfecting lentivirus plasmids without any envelope and used as a negative control. Next, we tested the transduction efficiency of the viruses on wild type 293 cells, given they express low level endogenous ACE2 ( Supplementary Fig. 2a, b) . While we found clearly defined infection of 293 cells with Spike-protein pseudovirus compared to bald virions, infection rate determined as GFP or RFP expression was relatively low (Fig. 3d) . We therefore generated human-ACE2 over-expressing 293 cells with a GFP reporter (ACE2-IRES-GFP) or fused to fluorescent mKO2 protein (ACE2-mKO2). ACE2 overexpression of ACE2-IRES-GFP or ACE2-mKO2 was confirmed by staining with CoV-2 Spike-protein fused with mouse Fc (mFc) and anti-mFc secondary antibody ( Supplementary Fig. 2a, b) . Indeed, these ACE2 overexpressing 293 cells (293-ACE2) were efficiently transduced with Spike protein pseudoviruses encoding either GFP or RFP (Fig. 3e) . The efficiency of Spike-protein pseudovirus infection was comparable in ACE2-IRES-GFP or ACE2-mKO2 fusion protein (Fig. 3e) , and therefore both were used in subsequent neutralization experiments. In addition, we also developed SARS Spike protein pseudotyped lentivirus, which similarly infected 293-ACE2 cells at almost 100% efficiency at higher virus supernatant volumes (Fig. 3f ). Neutralization of CoV-2 Spike protein pseudovirus with soluble ACE2, NAbs and COVID-19 plasma All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20148106 doi: medRxiv preprint We next investigated whether Spike protein pseudoviruses could be neutralized by soluble ACE2 (sACE) or Spike protein specific NAbs (Fig. 4a) . For this experiment, Spike protein pseudotyped CoV-2 and SARS pseudovirus were pre-cultured with different concentrations of sACE2 or NAbs, then added to 293-ACE2 cells. Subsequently, infection was determined 3 days post-infection based on GFP or RFP expression as described above. sACE2 neutralized both CoV-2 and SARS pseudovirus infections in a dose dependent manner (Fig. 4b, c) , although neutralization of CoV-2 was slightly better than that of SARS pseudoviruses (Fig. 4b , c, and Supplementary Fig. 3a) . Furthermore, Spike-RBD specific NAbs neutralized CoV-2 pseudovirus entry much more efficiently than sACE2 but had no effect on SARS pseudovirus (Fig. 4c) . We also observed measurable differences in the neutralizing activity of three different Nabs and 2 different soluble Ace2 proteins from two different sources (Fig. 4d) , showing the utility of this assay for such screening. Taken together, these experiments demonstrate that the combination of pseudotyped viruses and 293-ACE2 cells can be used to generate highly sensitive CoV-2 and SARS neutralization assays. Using this approach, we then tested neutralization titers from COVID-19 patients or seropositive donors with serial dilution of their plasma. Accordingly, plasma samples were incubated with Spike pseudovirus and added to 293-ACE2 cells in 3-fold serial dilutions and infection was determined as described in Figure 4 . Healthy control plasma samples were used as negative controls whereas anti-S-RBD NAb served as a positive control (Fig. 5a) . None of the control plasma (n=20, 1 shown in Fig. 5a ) tested showed any neutralization activity, whereas patient plasma efficiently neutralized the virus to 10,000-fold serial dilution (Fig. 5a) . The 50% neutralization titer (NT50), was determined using the half-maximal inhibitory concentration values of plasma samples, normalized to control infections, from their serial dilutions. Importantly, the NT50 values of the subjects were much higher in hospitalized patients than outpatients (Fig. 5b) . NT50 values for hospitalized and ICU/deceased subjects were also up to 1000-fold higher than All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20148106 doi: medRxiv preprint convalescent plasma donors (Fig. 5b) . Hospitalized males and females, separately, also remained higher in their NT50 levels and no difference was observed within each group (Fig. 5c ). We also tested whether CoV-2 PCR+ plasma could neutralize the SARS pseudovirus. 14 plasma samples from hospitalized group were tested for their ability to neutralize CoV-2 and SARS pseudoviruses. Remarkably, some of the plasma samples also neutralized SARS pseudovirus, although less efficiently than CoV-2 pseudovirus (Fig. 5d) . Interestingly, NT50 levels of plasma samples for CoV-2 and SARS were positively correlated (Fig. 5e, Supplementary Fig. 3b) Correlations of CoV-2 neutralization, antibody levels and COVID-19 subject characteristics To better understand the associations between patient characteristics and the humoral immune response in COVID-19, we next determined correlations between antibody AUC levels, NT50 values and demographics of the study subjects. First, we assessed the correlation between NT50 values with S-RBD or Nucleocapsid antibody titers or their subclasses. All Igs including S-RBD IgG (! " = 0.85), Nucleocapsid IgG (! " = 0.72), S-RBD IgA (! " = 0.69) and S-RBD IgM (! " = 0.47) showed high correlation with NT50 values of each subject (Fig. 6a) . Among Ig subclasses specific to S-RBD; IgG1 (! " = 0.82), IgG3 (! " = 0.71) and IgG2 (! " = 0.67) and to less degree with IgG4 (! " = 0.52) also correlated with NT50 values (Fig. 6b) . Total S-RBD IgG, also correlated in similar fashion with other IgG isotypes, with IgG1 showing the highest positive correlation (! " = 0.97) ( Supplementary Fig. 4 ). Next, we correlated the antibody AUC levels and NT50 values of the subjects with their age. Subjects had significantly higher S-RBD IgG (! " = 0.61), Nucleocapsid IgG (! " = 0.46), S-RBD IgA (! " = 0.5) and NT50 (! " = 0.56) values, with increased age (Fig. 6c) . We also explored the All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20148106 doi: medRxiv preprint relationship between the number of days between PCR test result and blood draw correlated with antibody levels or NT50 values excluding the subjects that had less than 15 days or fewer between those dates to ensure the antibody levels had already reached their peak. Of note, there was a significant negative correlation between the number of days and the IgG or IgA to S-RBD, anti-nucleocapsid IgG or the NT50 values ( ! " = -0.67) (Fig. 6d) , suggesting a potential decline in antibody titers over time. The COVID-19 pandemic is continuing to spread globally unabated, including within the United States. There is an urgent need to better understand the immune response to the virus so that effective immune-based treatments and vaccines can be developed 16, 17 . Neutralization of the virus by antibodies (NAbs) is one of the goals to achieve protection against CoV-2 18 . Despite rapid development of many serological tests, important questions about the quality and quantity of seroprevalence in individuals remains still unclear 19,20 . Here, we developed highly sensitive and specific humoral assays that measure both the magnitude and neutralization capacity of antibody responses in COVID-19 patients. Every SARS-CoV-2 infected subject we tested (n=87) had detectable antibodies and all subjects except one exhibited neutralization; both of these qualities were completely absent in non-infected controls. However, there was a profound difference in antibody and neutralization titers among subjects, ranging in more than 1000-fold differences. Furthermore, we found that some COVID-19 patients with high antibody titers also had neutralizing antibodies for SARS, suggesting a high degree of cross-reactivity between these two virus Spike proteins. One of our key findings was clustering of antibody responses based on severity of the disease; as hospitalized patients showed much higher antibody levels and neutralization capacity than All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . outpatient subjects or convalescent plasma donors. This finding is consistent with recent reports suggesting that patients with more severe disease contain relatively higher antibodies for SARS-CoV-2 infection 2,21,22 . Interestingly, most of the convalescent plasma donors had much lower level of neutralizing antibodies (by at least an order of magnitude) than hospitalized patients, who would be the suitable recipients for such plasma transfer therapy. This finding raises the question of whether convalescent plasma transfers may actually provide benefit to severe COVID-19 patients by providing neutralizing antibodies. It may perhaps be more beneficial to identify donors with much higher neutralizing antibody titers for the plasma donation. As such, our findings point to the importance of having access to assays that have a large dynamic range to detect antibody responses in COVID-19 patients or seropositive individuals. This neutralization assay also revealed differences in commercial antibodies to CoV-2 in their capacity to block virus entry, and as such can be used for rapid identification or generation of synthetic NAbs. In addition to measuring neutralization titers, the pseudoviruses can be used to probe cells that have the potential to be infected with CoV-2, given lentiviruses can infect most cell types and does not require cell division to integrate into the genome. This infection assay may also be used to screen small molecules that may impact virus cell entry. Along with CoV-2, we also developed a pseudotyped lentivirus with SARS Spike protein, which was equally efficient at infecting ACE2 overexpressing cells. This finding is consistent with results that CoV-2 Spike protein in complex binding with human ACE2 (hACE2) is similar overall to that observed for SARS 23 . There was however slightly better neutralization of CoV-2 cell entry than SARS with soluble ACE2, which could be due to key residue substitutions in CoV-2 creating a slightly stronger interaction and thus higher affinity for receptor binding than SARS Spike protein 23 . Accordingly, we also tested the ability of hospitalized COVID-19 patient plasma for SARS neutralizing capacity and found significant SARS-specific neutralization in COVID-19 All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20148106 doi: medRxiv preprint patients who also had high neutralization activity for CoV-2. Indeed, there was a very high level of correlation between titers of both viruses from the same donors (Fig. 5e) . Given that the two viruses share ~75% identical amino acids in their Spike proteins and there are conserved epitopes between them 24 , it is conceivable that some of the CoV-2 NAbs have cross-neutralizing activity 25,26 . This discrepancy could be due to differences in sensitivity in our respective assays, since the SARS neutralization was about an order of magnitude lower than the CoV-2 entry block. It is noteworthy that a recent study showed a NAb developed for SARS was highly effective at neutralizing CoV-2 27 . The use of flow cytometry bead based fluorescent system that detects Spike or Nucleocapsid protein bound antibodies provides a high-throughput assay with a very high dynamic range and sensitivity, as it could detect antibodies from some subjects at up to a million-fold dilution of the plasma. This assay is also scalable and can also be easily adaptable to other viral antigens. Using a flow cytometry platform is also important in that the assay can further be developed in a single panel to identify all antibody isotypes simultaneously and to complement flow cytometric immune phenotyping of COVID-19 patients. The high sensitivity and specificity of our assay has allowed us to correlate the Spike protein RBD-specific antibody levels with neutralization titers, which showed very high concordance, thus can be utilized as a proxy for neutralization in a clinical setting. Furthemore, bead-based immunoassay can also be further developed to screen for antibodies reacting to other CoV-2 antigens simultaneously and can be useful to identify antibodies that cross-react between different species of coronavirus proteins. Determining other isotypes such as IgA and IgG subclasses may also help in future mechanistic studies. It is clear that the dominant antibody response in almost all donors was IgG1, but some also show high IgA and IgG2-4, at varying levels. In particular, it is interesting to note that, in contrast to Spike protein-specific IgG, IgA antibody levels are not higher between hospitalized All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20148106 doi: medRxiv preprint and outpatients, and in fact are strikingly lower in ICU/deceased patients (Fig. 2e) . However, another study showed IgA antibodies, but not IgG, increased in severe patients 28 . While the significance of these findings or discrepancy are not yet clear, it is conceivable that given the importance of IgA antibodies in providing immunity on mucosal surfaces within the respiratory system, CoV-2 RBD-spike protein specific IgA levels may also play an important role in upper and lower respiratory system, or perhaps also in gut, of COVID-19 patients 29,30 . There are also several potential practical implications to our findings. First, the patient population with the highest risk factors for severe outcomes from infection such as age and co-morbid conditions had the highest antibody titers as well as neutralization of the virus. This is also the case for those patients who had lethal disease. It is therefore possible that surviving COVID-19 may require non-antibody dependent factors or that producing too much antibody may even have deleterious effects. Potential antibody-dependent enhancement phenomenon by triggering Fc receptors on macrophages 31 . In this regard, it is interesting to note that a bruton tyrosine kinase (BTK) inhibitor, that targets Fc-receptor signaling in macrophages, is being tested in a randomized clinical trial 32 . Another interesting observation is that further out from the infection, there appears to be less antibody response. Although it will be important to follow the same individual subject convalescent plasma over time to better assess this finding, our data point towards a relatively short-lived antibody response to COVID-19. Thus, understanding the mechanism of survival from COVID-19 and immune response dynamics will be critical, in better prediction of outcomes as well as assaying for a protective response to potential vaccines. In conclusion, the assays developed herein can have a utility in uncovering dynamic changes in the antibody levels in SARS-CoV-2 infected subjects over time, in responses to vaccines, and as potential clinical determinants for plasma or antibody therapies for COVID-19 patients. All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20148106 doi: medRxiv preprint Anti-hIgG-Fc C A All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20148106 doi: medRxiv preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20148106 doi: medRxiv preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20148106 doi: medRxiv preprint Statistical significances were determined using two-tailed Mann-Whitney U test. All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20148106 doi: medRxiv preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20148106 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20148106 doi: medRxiv preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . CoV-2 and SARS pseudovirus neutralization with soluble ACE2. CoV-2 RFP and SARS GFP pseudoviruses were preincubated with soluble ACE2 for 1 hour and added to 293 cells expressing ACE2-IRES-GFP or ACE2-mKO2 fusion respectively. c. Neutralization of CoV-2 and SARS with S-RBD specific antibodies and soluble ACE2 (sACE2). Viruses were pre-incubated with antibodies or soluble ACE2 for 1 hour at the concentrations shown and subsequently added to target cells. Expression of RFP was determined at day 3 post-infection. Infection percentages were normalized to negative controls. d. Neutralization of CoV-2 pseudoviruses using 3 different S-RBD NAbs and soluble ACE2 (sACE2) protein from two different sources. Representative experiment out of two is shown. All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . S-RBD NAb 10 µg/mL 1 µg/mL 0. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20148106 doi: medRxiv preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20148106 doi: medRxiv preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20148106 doi: medRxiv preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20148106 doi: medRxiv preprint SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor The research in this study was supported by National Institute of Health (NIH) grants R01AI121920, U54 NS105539 and U19 AI142733 to D.U. We thank Tina Vaziri for critical reading.